Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy

In trial (n=2139), dapagliflozin improved outcomes (hospitalisation or urgent visit requiring IV therapy or CV death) irrespective of use/no use of glucose-lowering therapy (GLT) or by GLT type used in patients with type 2 diabetes and heart failure with reduced ejection fraction


Diabetes Care